Identification of Serum Level of Glutathione Peroxidase 4

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

85 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-09-01

Study Completion Date

2027-07-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

* Analysis of the level of glutathione peroxidase 4 (GPX4) in ankylosing spondylitis and axial psoriatic arthritis patients.
* The association of glutathione peroxidase 4 (GPX4) with disease activity and severity in ankylosing spondylitis and axial psoriatic arthritis patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Ferroptosis Role in the Pathophysiology of Systemic Lupus Erythematosus

NCT07260942

Systemic Lupus Erythematosus

NOT_YET_RECRUITING NA

Autotaxin as Abiomarker in Systemic Lupus Erythematosus Patients

NCT06063668

SLE (Systemic Lupus)

NOT_YET_RECRUITING

The Diagnostic Utility of T Immunoglobulin G and T Immunoglobulin M Biomarkers in Patients With Systemic Lupus Erythematosus Disease : Associations With Disease Activity and Damage

NCT07136337

Systemic Lupus Erythematosus

NOT_YET_RECRUITING NA

Evaluation of Serum Galectin-9 Level in Systemic Lupus Erythematosus Patients and it's Association With Disease Activity and Organ Damage

NCT04558814

Systemic Lupus Erythematosus

UNKNOWN NA

Circulating Plasmablast in Diagnosis and Relapse Prediction of IgG4-RD

NCT04539197

Plasmablast/Plasma Cells in Diagnosis of IgG4-RD Plasmablast/Plasma Cells in Relapse Prediction of IgG4-RD

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Ferroptosis, first reported by Dixon et al. in 2012, is a form of non-apoptotic cell death driven by iron-dependent lipid reactive oxygen species (ROS) and accelerated by the accumulation of lipid peroxides, ultimately leading to oxidative damage to phospholipid membranes and cell death .

Ferroptosis could be induced by iron metabolism disorder, lipid peroxidation accumulation, deficiency of glutathione (GSH) and inactivation of the antioxidant enzyme glutathione peroxidase 4 (GPX4).

The morphological features of ferroptotic cells manifest as an aberrant mitochondrial ultrastructure, including a reduction in mitochondrial volume, an increase in mitochondrial membrane density, and the disappearance of mitochondrial cristae in ferroptotic cells .

Recent studies have increasingly reported on complex associations between ferroptosis and the immune system . The regulatory activity of ferroptosis in immune function and inflammation is multifaceted and involves innate, acquired, and autoimmunity.

Accumulating evidence in recent times has shown an association of ferroptosis with the pathogenesis and development of autoimmune diseases .

Spondyloarthropathy comprises a group of chronic inflammatory rheumatic diseases, including ankylosing spondylitis, reactive arthritis (Reiter syndrome), arthritis or spondylitis associated with inflammatory bowel disease, and psoriatic arthritis, as well as undifferentiated spondyloarthritis. These afflictions predominantly affect the axial skeleton, causing pain and stiffness.

Currently, research on ferroptosis is still in its early stages; therefore, exploring the pathogenesis of ferroptosis and its role in various diseases, and proposing effective and targeted treatment methods have significant theoretical significance and practical value.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Spondyloarthropathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ankylosing Spondylitis patients

Identification of Glutathione Peroxidase 4 in blood.

Blood sample

Intervention Type DIAGNOSTIC_TEST

Blood sample from each subject to detect Glutathione Peroxidase 4.

Axial Psoriatic Arthritis Patients

Identification of Glutathione Peroxidase 4 in blood.

Blood sample

Intervention Type DIAGNOSTIC_TEST

Blood sample from each subject to detect Glutathione Peroxidase 4.

healthy controls

Identification of Glutathione Peroxidase 4 in blood.

Blood sample

Intervention Type DIAGNOSTIC_TEST

Blood sample from each subject to detect Glutathione Peroxidase 4.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood sample

Blood sample from each subject to detect Glutathione Peroxidase 4.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients diagnosed as ankylosing spondylitis according to ASAS criteria . \[13\]
* Patients diagnosed as psoriatic arthritis according to CASPAR criteria. \[14\]
* Age (\>18).

Exclusion Criteria

* Patient with other autoimmune Rheumatic diseases.
* patients with any of the following conditions: I) severe liver and kidney dysfunction; II) hematopoietic diseases; III) infectious diseases; IV) tumors; or V) other wasting diseases. \[15\]
* patients received certain drugs (for example, sulfasalazine, artemisinin, statins), and experimental reagents (such as erastin) .\[16\]

Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No